Human intervention study to examine interactions between alpha-linolenic acid and quercetin

Human intervention study to examine interactions between alpha-linolenic acid and quercetin - AlaQu

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00005076

Enrollment

Registered

2013-08-01

Start date

2013-05-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Group 1: alpha-Linolenic acid (3 g/d

ingestion from rapeseed oil) and placebo (from hart gelatine capsules, 0 mg quercetin)

duration: 8 weeks

8-week wash-out period between both supplementation periods Group 2: alpha-Linolenic acid (3 g/d

ingestion from rapeseed oil) and quercetin (from hart gelatine capsules, 150 mg/d)

8-week wash-out period between both supplementation periods

Eligibility

Sex/Gender

All

Age

19 Years to 35 Years

Inclusion criteria

Inclusion criteria: metabolically healthy, normal body weight

Exclusion criteria

Exclusion criteria: Metabolic diseases (e.g. diabetes mellitus), overweight, obesity

Design outcomes

Primary

Measure	Time frame
Fatty acid composition (blood); measurement at the beginning of the intervention periods (week 0), after 4 weeks (halftime) and at the end of the intervention periods (week 8)	—

Secondary

Measure	Time frame
systolic and diastolic blood pressure, measurement at the beginning of the intervention periods (week 0), after 4 weeks (halftime) and at the end of the intervention periods (week 8); parameters of metabolism (triglycerides, cholesterol, LDL, HDL, apolipoproteine B and A1, glucose, C-reactive protein, antioxidants, oxidized LDL) at the beginning (week 0) and end (week 8) of the intervention periods.	—

Measure

Time frame

systolic and diastolic blood pressure, measurement at the beginning of the intervention periods (week 0), after 4 weeks (halftime) and at the end of the intervention periods (week 8); parameters of metabolism (triglycerides, cholesterol, LDL, HDL, apolipoproteine B and A1, glucose, C-reactive protein, antioxidants, oxidized LDL) at the beginning (week 0) and end (week 8) of the intervention periods.

—

Countries

Germany

Contacts

Public ContactSarah Egert

Universität Bonn IEL Ernährungsphysiologie

s.egert@uni-bonn.de0228 / 73 3748

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026